August 31, 2020 09:29 AM EDTUpdated 09:52 AM
R&D

As­traZeneca looks to widen its lead over SGLT2 ri­vals with an­oth­er round of land­mark da­ta

Nicole DeFeudis

Editor

Com­pe­ti­tion be­tween SGLT2 in­hibitors in the chron­ic kid­ney dis­ease field just got more in­ter­est­ing. This week­end, As­traZeneca went to the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy’s 2020 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

A service from the Financial Times